Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. - Wikidata - wikimedia - TriplyDB

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

http://www.wikidata.org/entity/Q53599393

about

Killing cancer cells by targeted drug-carrying phage nanomedicines Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine Linkers Having a Crucial Role in Antibody-Drug Conjugates Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems Antibody-drug conjugates as novel anti-cancer chemotherapeutics Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine Targeting CD19 in B-cell lymphoma: emerging role of SAR3419 From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates Antibody drug-conjugates targeting the tumor vasculature: Current and future developments Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors A mechanistic tumor penetration model to guide antibody drug conjugate design Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production.High-content analysis of antibody phage-display library selection outputs identifies tumor selective macropinocytosis-dependent rapidly internalizing antibodies.The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.Tracking Antibody Distribution with Near-Infrared Fluorescent Dyes: Impact of Dye Structure and Degree of Labeling on Plasma Clearance.Trastuzumab emtansine: mechanisms of action and drug resistance Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.The development of potential antibody-based therapies for myeloma Protease-activated drug development.Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Drug target interaction of tubulin-binding drugs in cancer therapy.Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer.Targeted estrogen delivery reverses the metabolic syndrome.Monoclonal antibodies in the treatment of pancreatic cancer.

P2860

Q21256651-942AF69D-A2DA-4DD9-87B3-D103E6C69B6D Q24632855-C577F3C0-C8BB-4F4B-87CC-54CF56840AC0 Q26747729-F54F1ACD-9FD5-4700-87D3-430D832C5EAB Q26752763-42A1AA4E-CC99-44F8-AF97-3F8BC3BE99A9 Q26780335-F78986D6-2815-40A0-BE62-9E5601EDED2E Q26782485-E4674D3C-87A9-4C39-99FE-588CFD609394 Q26800175-A70D28A1-10DE-49A2-811E-66BE3EA186BE Q27007486-2F9D38AA-0C4D-4FD0-8D86-1D08A1E093CB Q27015048-93D3DC3B-03EC-413E-B4CF-07A5FD1FF43B Q27027562-A246C36B-2FE6-4B47-A634-E7DD057794D6 Q28082921-E61C9763-62A4-45DC-AAB2-26EEC8220892 Q28083123-1773EECA-7E63-464D-924F-F3B14C84ABBB Q28270261-AA9E932E-A00E-4C79-8019-D8226D21881E Q28474893-37622BB7-9BA1-426C-9D7E-541E08D701E9 Q28544636-ED7DF7C3-8A60-4F8E-A5C1-5CCFE061A7AF Q28544658-B89BE82D-AC55-4B87-9131-6958312CDAD4 Q28546010-BE8A877F-B850-43D9-94D3-027A68C15FF8 Q28660580-3148BB0E-3ADC-4528-9B50-85EE34FC868E Q28829301-DBD686B2-1A90-44FD-AE80-B32DDF513140 Q30524836-1C3A5CBB-B781-448A-B46E-C349F2989FA6 Q30605298-FD37422E-04D1-470D-96D5-8DB49B6A0009 Q33409083-4D61E95D-732C-4989-AB00-1CC8B28091EE Q33433942-AD5D7A0E-0668-489B-8165-CD17D0ACA22F Q33635071-ABFCC9F9-529C-45DA-8B6B-A4E4BBFED8AB Q33759627-B3C07801-94A1-4046-8D4C-AC7E4166CEC3 Q33873317-4F15523A-F787-4BA7-83B1-AC4DD4C6684D Q34281123-7AD84F93-7D70-452B-9FA8-FD89BA47B6F2 Q34389275-D2FE1993-49E0-4C19-B96D-0981DE9F825A Q34655256-DFF686F6-4A5B-4E22-927A-7DF5A8CED569 Q35459059-9D5C77F4-9F9E-461C-9249-56ED38AFEE00 Q35788245-AC0D2C9B-9C4B-4EB8-9EF7-7384594DA5C3 Q35811508-0022C11D-A68B-41B5-BD97-D66FFF10D2DD Q35892045-5508732D-6230-4643-AFE8-1AF27606CEDF Q36636645-688D20DB-F762-4079-BD1E-1849CFD83652 Q36653094-4BA735C6-708D-4436-8DC1-5969762F9D2A Q36745332-D0DBE749-F39D-4064-9067-614C4FBB15EB Q37066113-2E742C99-B35B-4EB9-9AED-2D77E696F2A3 Q37100575-1FB096AB-46B3-48E8-AE3E-30C0D9CA707D Q37134063-DEAC5F65-509B-47EE-AC4D-A31F7B7CE116 Q37355568-BE28941A-20A5-4F46-80AC-F1EAB5C32F9B

P2860

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

http://www.wikidata.org/entity/Q53599393

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Antibody-maytansinoid conjugat ...... dent intracellular processing.

@en

Antibody-maytansinoid conjugat ...... dent intracellular processing.

@nl

type

label

Antibody-maytansinoid conjugat ...... dent intracellular processing.

@en

Antibody-maytansinoid conjugat ...... dent intracellular processing.

@nl

prefLabel

Antibody-maytansinoid conjugat ...... dent intracellular processing.

@en

Antibody-maytansinoid conjugat ...... dent intracellular processing.

@nl

P1433

Q53599393-3F6BB8A4-7C4A-4AB1-B049-19AE67BC6D50

P1476

Q53599393-07875144-4933-448B-AB6C-C59393C7AD8F

P2093

Q53599393-02B78979-E4B6-4509-A127-CEFFD28A6608

Q53599393-31C3DC3D-02CC-4A80-9C3F-15EBE7B18EF6

Q53599393-3C4C5C33-9F56-4EAC-9579-C5D725A65971

Q53599393-44856D13-0EFF-4AE3-82F6-72182AB33F75

Q53599393-662D19A1-8940-406D-984A-32A1E8FB7F2B

Q53599393-CC84023F-9092-4F73-8450-60386C24D4F6

Q53599393-CEB6DAD9-CBE4-4B04-A6B3-15C7A91DC930

Q53599393-EB08E8D7-8F1E-46D6-8633-187829634F81

Q53599393-F5D18DFC-8F25-4DFD-96D2-166DC71B01FB

P304

Q53599393-BFAEB28F-4006-4C5D-9F5C-AEEFA7D1E9E0

P31

Q53599393-CF951087-5187-47FD-8EEB-A1AB6EA3367E

P356

Q53599393-9190348F-F952-4237-A80E-9DC427AEFCA7

P407

Q53599393-545E15D2-9025-4A5A-A9AA-9A3D9C6B8F06

P433

Q53599393-4A1540D5-4D9E-485E-A364-CE1844E1C1F4

P478

Q53599393-37832A5F-09D7-4462-B53E-9F4FB2E38BE2

P577

Q53599393-58472988-A34A-46D5-92A0-6D4859918963

P698

Q53599393-43550DF9-6532-4787-B867-D5A9ACBA03B0

P921

Q53599393-EF72D5A7-DE58-42AB-9748-1A4749BF3889

P356

0008-5472.CAN-05-4489

P1433

Cancer Research

P1476

Antibody-maytansinoid conjugat ...... dent intracellular processing.

@en

P2093

Hans K Erickson

http://www.w3.org/2001/XMLSchema#string

Karen Hoffman

http://www.w3.org/2001/XMLSchema#string

Lisa M Garrett

http://www.w3.org/2001/XMLSchema#string

Peter U Park

http://www.w3.org/2001/XMLSchema#string

Robert J Lutz

http://www.w3.org/2001/XMLSchema#string

Victor S Goldmacher

http://www.w3.org/2001/XMLSchema#string

Walter A Blättler

http://www.w3.org/2001/XMLSchema#string

Wayne C Widdison

http://www.w3.org/2001/XMLSchema#string

Yelena V Kovtun

http://www.w3.org/2001/XMLSchema#string

P304

4426-4433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-05-4489

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16618769

http://www.w3.org/2001/XMLSchema#string

P921